Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.
Status:
Completed
Trial end date:
2019-11-23
Target enrollment:
Participant gender:
Summary
KAE609 will be evaluated primarily for hepatic safety of single and multiple doses in
sequential cohorts with increasing doses.This study aims to determine the maximum safe dose
of the investigational drug KAE609 in malaria patients.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Collaborator:
Supported by Wellcome Trust via Grant # Grant Number 207813/Z/17/Z
Treatments:
Artemether Artemether-lumefantrine combination Artemether, Lumefantrine Drug Combination Artemisinins Lumefantrine